Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 11:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Central Line Clear all
Active, not recruiting Phase 1 Interventional

GDNF Gene Therapy for Parkinson's Disease

NCT04167540
View directory record Official record
Conditions
Parkinson's Disease
Interventions
AAV2-GDNF
Biological
Lead sponsor
Brain Neurotherapy Bio, Inc.
Industry
Eligibility
35 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Irvine, California • San Francisco, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Sep 13, 2026, 11:23 AM EDT
Completed Phase 2 Interventional

Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

NCT00651508
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
KOS-1584
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Sep 13, 2026, 11:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

NCT01258608
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Mapatumumab, Placebo, Sorafenib
Drug
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
9
States / cities
Aurora, Colorado • Shreveport, Louisiana • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Sep 13, 2026, 11:23 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients

NCT02568046
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Sym004, FOLFIRI
Drug
Lead sponsor
Symphogen A/S
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Los Angeles, California • San Diego, California • Washington D.C., District of Columbia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 13, 2026, 11:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer

NCT03439462
View directory record Official record
Conditions
Colorectal Cancer Metastatic
Interventions
nab-sirolimus
Drug
Lead sponsor
Aadi Bioscience, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
6
States / cities
Scottsdale, Arizona • New Orleans, Louisiana • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Sep 13, 2026, 11:23 AM EDT
Completed Phase 3 Interventional Results available

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

NCT02625610
View directory record Official record
Conditions
Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction
Interventions
Avelumab, Oxaliplatin, 5-Fluorouracil, Leucovorin, Capecitabine, Best supportive care
Drug · Other
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
35
States / cities
Bakersfield, California • Fullerton, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Sep 13, 2026, 11:23 AM EDT
Terminated Phase 2 Interventional Results available

LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC

NCT05537402
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Atezolizumab and bevacizumab, transarterial chemoembolization (TACE) or transarterial radioembolization (TARE
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 13, 2026, 11:23 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

NCT05668988
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
sunvozertinib, Pemetrexed+carboplatin
Drug
Lead sponsor
Dizal Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
14
States / cities
Glendale, California • Vallejo, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 13, 2026, 11:23 AM EDT
Terminated Phase 2 Interventional Results available

A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

NCT05712356
View directory record Official record
Conditions
Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Bile Duct Cancer, Gall Bladder Cancer, Gall Bladder Carcinoma
Interventions
certepetide, Durvalumab, Cisplatin, Gemcitabine, FOLFOX regimen, Placebo
Drug
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
19
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 13, 2026, 11:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

NCT01124565
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
Interventions
RT001
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
3
States / cities
Birmingham, Alabama • San Diego, California • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Sep 13, 2026, 11:23 AM EDT
Terminated Not applicable Interventional Results available

The Pristine Post-Market Study

NCT05228132
View directory record Official record
Conditions
Kidney Failure, Chronic, Hemodialysis Complication, Hemodialysis Catheter Infection, Hemodialysis Access Failure, Central Venous Catheter Related Bloodstream Infection, End Stage Renal Disease
Interventions
Pristine™ Long-Term Hemodialysis Catheter
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
6
States / cities
Dothan, Alabama • New Haven, Connecticut • Shreveport, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Sep 13, 2026, 11:23 AM EDT
Completed Phase 3 Interventional

OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer

NCT00382811
View directory record Official record
Conditions
Fallopian Tube Cancer, Peritoneal Neoplasms, Ovarian Cancer
Interventions
phenoxodiol, carboplatin, placebo
Drug
Lead sponsor
MEI Pharma, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
37
States / cities
Tuscon, Arizona • Glendale, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2016 · Synced Sep 13, 2026, 11:23 AM EDT
Withdrawn Phase 2 Interventional

Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer

NCT00386516
View directory record Official record
Conditions
Cancer of the Bile Duct, Gallbladder Cancer
Interventions
GM-CT-01, 5-Fluorouracil
Drug
Lead sponsor
Galectin Therapeutics Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 13, 2026, 11:23 AM EDT
Completed Phase 1 Interventional

CNS10-NPC-GDNF for the Treatment of ALS

NCT02943850
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Stem cell (HPC) implantation, Stereotactic surgical device
Biological · Device
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Sep 13, 2026, 11:23 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

NCT02453282
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma NSCLC
Interventions
MEDI4736 (Durvalumab), MEDI4736 (Durvalumab)+Tremelimumab, Paclitaxel + Carboplatin, Gemcitabine + Cisplatin, Gemcitabine + Carboplatin, Pemetrexed + Cisplatin, Pemetrexed + Carboplatin, Tremelimumab
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
35
States / cities
Scottsdale, Arizona • Tucson, Arizona • Yuma, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 13, 2026, 11:23 AM EDT
Withdrawn Phase 4 Interventional

Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases

NCT00510627
View directory record Official record
Conditions
Metastatic Liver Cancer, Secondary Liver Cancer, Liver Neoplasm
Interventions
Radiofrequency Ablation (RFA), Chemotherapy
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 13, 2026, 11:23 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

NCT02369653
View directory record Official record
Conditions
Lymphoma, Acute Lymphoblastic Leukemia
Interventions
Apixaban, No systemic anticoagulant prophylaxis
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
1 Year to 17 Years
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
64
States / cities
Phoenix, Arizona • Duarte, California • Loma Linda, California + 56 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Sep 13, 2026, 11:23 AM EDT
Terminated Not applicable Interventional

Can Ultrasound be Used to Verify CVC Position and to Exclude Pneumothorax?

NCT00388375
View directory record Official record
Conditions
Catheterization, Central Venous
Interventions
Ultrasound
Procedure
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Oct 19, 2014 · Synced Sep 13, 2026, 11:23 AM EDT
Terminated Phase 1 Interventional

Safety and Efficacy of Tissue Plasminogen Activator (tPA) in Neonates and Infants

NCT00265005
View directory record Official record
Conditions
Thrombosis
Interventions
alteplase
Drug
Lead sponsor
University of Louisville
Other
Eligibility
28 Weeks to 66 Weeks
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Sep 13, 2026, 11:23 AM EDT
Completed Phase 2 Interventional

Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy

NCT04401774
View directory record Official record
Conditions
Primary Central Nervous System Lymphoma (PCNSL)
Interventions
Nivolumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 13, 2026, 11:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00968825
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
Interventions
Botulinum Toxin Type A, Placebo
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
30 Years to 60 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Sep 13, 2026, 11:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Parental Feelings About Their Child Needing a Central Line

NCT05842356
View directory record Official record
Conditions
Critical Illness, Children, Only, Stress
Interventions
Communication Technique 2
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Sep 13, 2026, 11:23 AM EDT
Completed Phase 2 Interventional Results available

Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer

NCT00089999
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Lapatinib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Sep 13, 2026, 11:23 AM EDT
Recruiting Phase 3 Interventional

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

NCT07555938
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cevostamab, Pomalidomide, Dexamethasone, Daratumumab, Elotuzumab, Carfilzomib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
9
States / cities
Duarte, California • Irvine, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 13, 2026, 11:23 AM EDT